Tackle the challenges of circulating tumor DNA (ctDNA) research and non-invasive prenatal testing (NIPT)


At the frontier of liquid biopsy, NIPT (noninvasive prenatal testing) is increasingly being used to screen and test chromosomal abnormalities by analyzing cell-free fetal DNA circulating in maternal blood. Similarly, since disease-specific mutations or alterations of the circulating cell-free DNA (cfDNA) are frequently found in serum samples of cancer patients, research into cctDNA testing as liquid biopsy is also rapidly expanding. However, detection and quantification of cfDNA is compromised by the release of genomic DNA (gDNA) from lymphocytes due to mechanical lysis or apoptosis during blood collection, storage and transport.

To tackle this challenge, PreAnalytiX®, a joint venture between BD® and QIAGEN, has developed the PAXgene® Blood ccfDNA System to integrate collection, stabilization and purification of circulating cell-free DNA. The system consists of the PAXgene Blood ccfDNA Tube and the QIAsymphony® PAXgene Blood ccfDNA Kit. The PAXgene Blood ccfDNA Tube, a plastic blood collection tube, contains a unique, non-crosslinking chemistry that preserves extracellular levels of cfDNA and prevents the release of intracellular DNA from cells into the plasma, while the QIAsymphony® PAXgene Blood ccfDNA Kit enables automated cfDNA extraction from up to 5 ml of plasma.

To help you catch up on this exciting new technology and other technologies developed at QIAGEN, we have scheduled a special 4-part webinar series on cfDNA extraction and detection, starting April 6.

Part 1: New technology and workflow for integrated collection, stabilization and purification of circulating cell-free DNA 
April 6, 1 p.m. EDT, 10 a.m. PDT, 6 p.m. GMT, 7 p.m. CEST
PreAnalytiX has developed the PAXgene Blood ccfDNA System, consisting of the PAXgene Blood ccfDNA Tube and the QIAsymphony PAXgene Blood ccfDNA Kit for automated circulating cfDNA extraction from up to 5 ml of plasma. In this webinar, this new technology development will be presented in comparison to other existing technologies.

Part 2: Overcome challenges of cfDNA with automated and standardized extraction processes
April 13, 1 p.m. EDT, 10 a.m. PDT, 6 p.m. GMT, 7 p.m. CEST
We present data on solutions for the following critical problems concerning the purification of cfDNA for research and molecular diagnostic applications:
• Pre-analytical workflow (blood processing) for analyzing cfDNA
• Optimization of cfDNA extraction from plasma samples: low target concentrations require efficient cfDNA enrichment from larger sample volumes
• Novel automated extraction of cfDNA using the QIAsymphony SP instrument for liquid biopsy diagnostic applications

Part 3: Sensitive mutation detection by sequencing circulating cell-free DNA
April 20, 1 p.m. EDT, 10 a.m. PDT, 6 p.m. GMT, 7 p.m. CEST
Sequence analysis of cfDNA using next-generation sequencing (NGS) technologies provides a highly sensitive method for detecting and characterizing somatic mutations in cancer samples. In this webinar, we will describe the technical challenges facing cfDNA sequencing and present an optimized workflow that combines high-efficiency NGS library construction, unbiased library amplification and target enrichment to sensitively and reliably detect mutations in cfDNA samples.

Part 4: Analysis and interpretation of cell-free DNA
April 27, 1 p.m. EDT, 10 a.m. PDT, 6 p.m. GMT, 7 p.m. CEST
Identification and monitoring of cancer mutations from cell-free DNA-Seq data is a key application in liquid biopsy. In this webinar, we will show how mutations can be best identified from this type of data and how they can be interpreted.


Trademarks: QIAsymphony® (QIAGEN Group); PAXgene®, PreAnalytiX® (PreAnalytiX GmbH); BD™ (Becton Dickinson and Company)


Wei Cao, Ph.D.

Senior Global Marketing Manager, Translational Sciences

Dr. Wei Cao joined QIAGEN in 2010 and currently leads the webinar program, presenting various topics on advanced techniques in biomedical research. She received her Ph.D. from Peking University in China in 2010, and conducted postdoctoral research at Weill Cornell Medical College in New York City. Before joining QIAGEN, Dr. Cao worked as a senior scientist in R&D in pharmaceutical and biotech, focusing on HIV, HCV and cancer drug discovery and development.

Your email address will not be published. Required fields are marked *